FDA Plant Inspection Delays Novo Nordisk Denecimig BLA Review Now

Facility remediation at a Novo Nordisk manufacturing site has stalled the FDA's BLA review of denecimig, a FVIIIa mimetic bispecific antibody for haemophilia A, with no revised action date yet communicated by the Agency. For plant heads and QA directors, the situation is a direct illustration of how pre-license inspection findings can suspend an otherwise clean regulatory package.

Novo submitted the BLA in September 2025, targeting a third-quarter 2026 regulatory decision. Following that submission, the FDA conducted a pre-license inspection of the manufacturing site and provided feedback on remediation requirements. The Agency has since confirmed that ongoing facility remediation activities are the sole cause of the review extension. Critically, the FDA has identified no deficiencies in the clinical efficacy or safety data generated through the FRONTIER clinical programme, which evaluated denecimig across adult and paediatric populations with haemophilia A, with or without inhibitors.

The operational read is unambiguous: a biologics package can clear clinical scrutiny entirely and still face an indeterminate hold driven by manufacturing site readiness. Under 21 CFR Part 211 and the pre-license inspection framework, the FDA's authority to withhold approval pending facility compliance is well-established, and the denecimig case reinforces that GMP conformance at the production site must be inspection-ready concurrent with, not subsequent to, BLA submission.

Novo has stated that the manufacturing site feedback does not affect other marketed products in its portfolio, limiting the compliance perimeter to the denecimig facility specifically. The company is actively implementing remediation activities in response to FDA requests and characterises the process as ongoing and collaborative. No financial guidance revision has been issued for 2026 as a result of the delay.

Pending a satisfactory remediation outcome and subsequent regulatory decision, Novo is targeting a US launch of denecimig in the first half of 2027, a window that leaves limited tolerance for further inspection cycles or additional agency requests before year-end.

Source: Novo Nordisk via GlobeNewswire, 2 October 2026.